CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Larimar Therapeutics, Inc. - LRMR CFD

3.50
3.24%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.06
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026235 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026235%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.004012 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004012%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Larimar Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 3.39
Open* 3.28
1-Year Change* 9.33%
Day's Range* 3.28 - 3.54
52 wk Range 2.18-6.85
Average Volume (10 days) 142.76K
Average Volume (3 months) 2.41M
Market Cap 135.23M
P/E Ratio -100.00K
Shares Outstanding 43.91M
Revenue N/A
EPS -0.76
Dividend (Yield %) N/A
Beta 0.50
Next Earnings Date Mar 12, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 1, 2023 3.50 0.22 6.71% 3.28 3.54 3.25
Nov 30, 2023 3.39 0.23 7.28% 3.16 3.43 3.16
Nov 29, 2023 3.23 -0.15 -4.44% 3.38 3.46 3.14
Nov 28, 2023 3.37 -0.01 -0.30% 3.38 3.48 3.28
Nov 27, 2023 3.51 0.08 2.33% 3.43 3.52 3.32
Nov 24, 2023 3.48 0.22 6.75% 3.26 3.58 3.26
Nov 22, 2023 3.28 0.19 6.15% 3.09 3.28 2.97
Nov 21, 2023 3.05 -0.05 -1.61% 3.10 3.16 3.01
Nov 20, 2023 3.11 -0.17 -5.18% 3.28 3.28 3.04
Nov 17, 2023 3.25 0.07 2.20% 3.18 3.41 3.15
Nov 16, 2023 3.04 0.17 5.92% 2.87 3.17 2.71
Nov 15, 2023 2.90 0.43 17.41% 2.47 2.95 2.47
Nov 14, 2023 2.50 0.06 2.46% 2.44 2.71 2.43
Nov 13, 2023 2.36 0.17 7.76% 2.19 2.38 2.18
Nov 10, 2023 2.37 0.21 9.72% 2.16 2.40 2.15
Nov 9, 2023 2.28 -0.42 -15.56% 2.70 2.70 2.23
Nov 8, 2023 2.75 -0.11 -3.85% 2.86 2.95 2.71
Nov 7, 2023 3.09 0.07 2.32% 3.02 3.13 2.95
Nov 6, 2023 3.08 0.01 0.33% 3.07 3.15 2.98
Nov 3, 2023 3.17 0.32 11.23% 2.85 3.17 2.85

Larimar Therapeutics, Inc. Events

Time (UTC) Country Event
Tuesday, March 12, 2024

Time (UTC)

12:30

Country

US

Event

Q4 2023 Larimar Therapeutics Inc Earnings Release
Q4 2023 Larimar Therapeutics Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 0 0 0
Revenue 0 0
Total Operating Expense 36.526 50.465 42.804 45.654 61.122
Selling/General/Admin. Expenses, Total 12.276 12.069 11.397 16.215 13.193
Research & Development 24.25 38.396 31.407 23.886 47.929
Operating Income -36.526 -50.465 -42.804 -45.654 -61.122
Interest Income (Expense), Net Non-Operating 0.248 -0.246
Net Income Before Taxes -35.355 -50.636 -42.482 -45.406 -61.368
Net Income After Taxes -35.355 -50.636 -42.482 -45.406 -61.368
Net Income Before Extra. Items -35.355 -50.636 -42.482 -45.406 -61.368
Net Income -35.355 -50.636 -42.482 -45.406 -61.368
Total Adjustments to Net Income
Income Available to Common Excl. Extra. Items -35.355 -50.636 -42.482 -45.406 -61.368
Income Available to Common Incl. Extra. Items -35.355 -50.636 -42.482 -45.406 -61.368
Diluted Net Income -35.355 -50.636 -42.482 -45.406 -61.368
Diluted Weighted Average Shares 25.7614 17.1643 11.8832 3.11227 2.68562
Diluted EPS Excluding Extraordinary Items -1.3724 -2.95008 -3.57498 -14.5894 -22.8506
Diluted Normalized EPS -1.3724 -2.95008 -3.57498 -12.8051 -22.8506
Total Extraordinary Items
Unusual Expense (Income) 5.553
Other, Net 1.171 -0.171 0.322
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Total Operating Expense 9.62 7.637 10.439 8.513 8.687
Selling/General/Admin. Expenses, Total 3.745 3.075 3.221 2.931 3.043
Research & Development 5.875 4.562 7.218 5.582 5.644
Operating Income -9.62 -7.637 -10.439 -8.513 -8.687
Other, Net 1.254 1.111 1.014 0.193 0.02
Net Income Before Taxes -8.366 -6.526 -9.425 -8.32 -8.667
Net Income After Taxes -8.366 -6.526 -9.425 -8.32 -8.667
Net Income Before Extra. Items -8.366 -6.526 -9.425 -8.32 -8.667
Net Income -8.366 -6.526 -9.425 -8.32 -8.667
Income Available to Common Excl. Extra. Items -8.366 -6.526 -9.425 -8.32 -8.667
Income Available to Common Incl. Extra. Items -8.366 -6.526 -9.425 -8.32 -8.667
Diluted Net Income -8.366 -6.526 -9.425 -8.32 -8.667
Diluted Weighted Average Shares 43.8976 43.8976 44.0969 22.2282 18.3389
Diluted EPS Excluding Extraordinary Items -0.19058 -0.14866 -0.21373 -0.3743 -0.4726
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.19058 -0.14866 -0.21373 -0.3743 -0.4726
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 120.739 72.204 97.952 71.503 121.33
Cash and Short Term Investments 118.428 70.097 92.638 70.261 118.066
Cash & Equivalents 26.825 70.097 68.148 27.211 49.331
Short Term Investments 91.603 0 24.49 43.05 68.735
Total Receivables, Net 0 0.208 0.243 1.536
Prepaid Expenses 2.311 1.899 5.314 0.999 1.728
Total Assets 126.405 78.667 104.686 80.734 121.762
Property/Plant/Equipment, Total - Net 3.689 4.455 4.976 7.872 0.375
Property/Plant/Equipment, Total - Gross 4.603 5.051 5.311 8.615 0.925
Accumulated Depreciation, Total -0.914 -0.596 -0.335 -0.743 -0.55
Other Long Term Assets, Total 1.977 2.008 1.758 1.359 0.057
Total Current Liabilities 10.705 8.846 8.992 12.19 13.306
Accounts Payable 1.686 1.66 2.634 0.632 3.59
Accrued Expenses 9.019 7.186 6.358 4.285 4.261
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 7.273 5.455
Total Liabilities 15.502 14.254 14.994 27.11 28.491
Total Long Term Debt 0 0 0 8.464 15.185
Long Term Debt 8.464 15.185
Total Equity 110.903 64.413 89.692 53.624 93.271
Redeemable Preferred Stock 0 0
Common Stock 0.043 0.018 0.015 0.037 0.037
Additional Paid-In Capital 262.496 180.645 155.29 449.903 444.212
Retained Earnings (Accumulated Deficit) -151.605 -116.25 -65.614 -396.351 -350.945
Other Equity, Total -0.031 0 0.001 0.035 -0.033
Total Liabilities & Shareholders’ Equity 126.405 78.667 104.686 80.734 121.762
Total Common Shares Outstanding 43.2692 17.7104 15.3677 3.12042 3.10714
Other Liabilities, Total 4.797 5.408 6.002 6.456
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 98.48 106.478 113.464 120.739 127.127
Cash and Short Term Investments 95.59 104.2 111.524 118.428 124.699
Cash & Equivalents 38.721 94.321 111.524 26.825 86.047
Short Term Investments 56.869 9.879 0 91.603 38.652
Prepaid Expenses 2.89 2.278 1.94 2.311 2.314
Total Assets 103.952 111.716 118.907 126.405 133.015
Property/Plant/Equipment, Total - Net 3.499 3.255 3.472 3.689 3.906
Property/Plant/Equipment, Total - Gross 4.643 4.323 4.464 4.603 4.742
Accumulated Depreciation, Total -1.144 -1.068 -0.992 -0.914 -0.836
Other Long Term Assets, Total 1.973 1.983 1.971 1.977 1.982
Total Current Liabilities 6.558 7.275 8.01 10.705 9.42
Accounts Payable 0.756 2.344 0.695 1.686 0.849
Accrued Expenses 5.802 4.931 7.315 9.019 8.571
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 11.24 11.786 12.666 15.502 14.353
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 4.682 4.511 4.656 4.797 4.933
Total Equity 92.712 99.93 106.241 110.903 118.662
Redeemable Preferred Stock 0
Common Stock 0.043 0.043 0.043 0.043 0.043
Additional Paid-In Capital 268.223 266.372 264.329 262.496 260.839
Retained Earnings (Accumulated Deficit) -175.561 -166.497 -158.131 -151.605 -142.18
Other Equity, Total 0.007 0.012 0 -0.031 -0.04
Total Liabilities & Shareholders’ Equity 103.952 111.716 118.907 126.405 133.015
Total Common Shares Outstanding 43.9059 43.2692 43.2692 43.2692 43.2692
Total Receivables, Net 0 0.114
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -35.355 -50.636 -42.482 -45.406 -61.368
Cash From Operating Activities -27.569 -42.105 -42.199 -40.783 -51.487
Cash From Operating Activities 0.318 0.326 0.155 0.263 0.261
Non-Cash Items 5.845 5.458 2.171 4.745 9.027
Cash Interest Paid 1.217 1.144
Changes in Working Capital 1.623 2.747 -2.043 -0.385 0.593
Cash From Investing Activities -90.96 24.169 17.09 25.263 -6.867
Capital Expenditures -0.1 -0.333 -0.062 -0.764 -0.108
Other Investing Cash Flow Items, Total -90.86 24.502 17.152 26.027 -6.759
Cash From Financing Activities 75.257 19.885 93.587 -5.261 66.908
Financing Cash Flow Items 0 17.995 0 -0.312
Issuance (Retirement) of Stock, Net 75.257 19.885 75.592 0.194 67.22
Issuance (Retirement) of Debt, Net -5.455 0
Net Change in Cash -43.272 1.949 68.478 -20.781 8.554
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -6.526 -35.355 -25.93 -17.61 -8.943
Cash From Operating Activities -7.551 -27.569 -20.897 -15.019 -7.533
Cash From Operating Activities 0.078 0.318 0.24 0.163 0.082
Non-Cash Items 1.217 5.845 4.91 3.307 1.635
Changes in Working Capital -2.32 1.623 -0.117 -0.879 -0.307
Cash From Investing Activities 92.25 -90.96 -38.726 -35.342 0
Capital Expenditures -0.1 -0.1 -0.1
Other Investing Cash Flow Items, Total 92.25 -90.86 -38.626 -35.242 0
Cash From Financing Activities 0 75.257 75.573 0 0
Financing Cash Flow Items 0 0 0
Net Change in Cash 84.699 -43.272 15.95 -50.361 -7.533
Issuance (Retirement) of Stock, Net 75.257 75.573
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Deerfield Management Company, L.P. Hedge Fund 39.1459 16941357 0 2023-06-30 MED
Cowen Investment Management LLC Investment Advisor/Hedge Fund 7.8897 3414468 668203 2023-06-30 HIGH
Verition Fund Management LLC Hedge Fund 6.2774 2716713 777891 2023-06-30 HIGH
Janus Henderson Investors Investment Advisor/Hedge Fund 5.0636 2191411 745685 2023-08-10 LOW
Woodline Partners LP Hedge Fund 3.8863 1681913 0 2023-06-30 HIGH
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.2155 1391601 100191 2023-06-30 LOW
Opaleye Management Inc. Hedge Fund 3.2118 1390000 -11000 2023-06-30 MED
BlackRock Institutional Trust Company, N.A. Investment Advisor 3.0264 1309766 991499 2023-06-30 LOW
Citadel Advisors LLC Hedge Fund 2.7189 1176655 500217 2023-06-30 LOW
Point72 Asset Management, L.P. Hedge Fund 1.9387 839000 384000 2023-06-30 HIGH
Mangrove Partners Hedge Fund 1.862 805815 0 2023-06-30 MED
Adage Capital Management, L.P. Hedge Fund 1.5058 651680 0 2023-06-30 LOW
Hamilton (Thomas Edward) Individual Investor 1.4102 610313 0 2023-03-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.2398 536560 264596 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.9943 430317 324114 2023-06-30 LOW
Two Sigma Investments, LP Hedge Fund 0.9371 405541 -52478 2023-06-30 HIGH
UBS O'Connor LLC Hedge Fund 0.8399 363505 151011 2023-06-30 HIGH
Dafna Capital Management, LLC Hedge Fund 0.8096 350373 113500 2023-06-30 LOW
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 0.7369 318909 153467 2023-06-30 LOW
Atlas Venture Venture Capital 0.6751 292184 0 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Larimar Therapeutics, Inc. Company profile

About Larimar Therapeutics Inc

Larimar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its cell penetrating peptide technology platform. The Company's protein replacement therapy platform is intended to deliver missing proteins inside the machinery of cells to treat devastating rare diseases that is ineffective or no treatments available. Its cell penetrating peptide ( CPP) technology platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets that has the potential to enable the treatment of other rare and orphan diseases. The Company's lead product candidate, CTI-1601, is a recombinant fusion protein intended to deliver human frataxin ( FXN), an essential protein to the mitochondria of patients with Friedreich’s ataxia. CTI-1601 is in Phase I clinical program.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Larimar Therapeutics Inc revenues was not reported. Net loss increased 47% to $41.5M. Higher net loss reflects Research and Development increase of 50% to $30.6M (expense), Stock-based Compensation in SGA increase from $709K to $2.5M (expense), Stock-based Compensation in R&D increase from $442K to $1.5M (expense).

Equity composition

Common Stock, $0.001 Par, 06/14, auth. 115M shares,. 20,807,012 issd,. Insiders owns approx. 28.83%.

Industry: Bio Therapeutic Drugs

Three Bala Plaza East. Suite 506
BALA CYNWYD
PENNSYLVANIA 19004
US

Income Statement

  • Annual
  • Quarterly

News

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023
GBP

UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

10:48, 21 November 2023

People also watch

BTC/USD

38,841.75 Price
-0.020% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

US100

16,001.20 Price
+0.470% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 7.0

XRP/USD

0.62 Price
+0.250% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Oil - Crude

74.50 Price
-1.560% 1D Chg, %
Long position overnight fee -0.0136%
Short position overnight fee -0.0083%
Overnight fee time 22:00 (UTC)
Spread 0.040

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading